Trial Profile
ASTIMS: Autologous Stem cell Transplantation International Multiple Sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2012
Price :
$35
*
At a glance
- Drugs Mitoxantrone (Primary) ; Autologous stem cell therapy; Carmustine; Cytarabine; Etoposide; Haematopoietic stem cell therapy; Melphalan
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ASTIMS
- 09 Nov 2012 New trial record